drugset / Trial / NCT02359292

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers

NCT02359292

Phase 1 Completed 50 enrolled Chiesi Farmaceutici S.p.A.
RandomizedCrossoverOpen-labelTreatment

Summary

The study is performed to evaluate the total systemic exposure and lung bioavailability of CHF 5993 pMDI combination, in healthy volunteers subjects.

Timeline

Start
2015-02
Primary completion
2015-04
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CHF 5993 Other / unclassified Inhaled
Subject Charcoal Block Unknown

Indications